NasdaqGM:OCULPharmaceuticals
Ocular Therapeutix's (OCUL) Investor Day to Spotlight AXPAXLI Program's Potential in Retinal Disease Treatment
Ocular Therapeutix, Inc. recently announced it will host an Investor Day on September 30, 2025, in New York City, featuring company leaders and global retina experts providing clinical and commercial updates on its AXPAXLI™ program for retinal diseases.
This event will spotlight potential advantages of AXPAXLI™, including differentiated superiority labeling and global opportunities addressing wet age-related macular degeneration and other high-burden retinal conditions.
We'll examine how the...